Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review
Archives of Dermatological Research · 2025
DOI: 10.1007/s00403-024-03694-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Layna Mager und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University College of Medicine, Columbus, OH, USA. Hauptthemen laut MEDLINE: Keratoacanthoma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ohio State University College of Medicine, Columbus, OH, USA.
- Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.
- Department of Pathology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
- Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA. Brittany.Dulmage@osumc.edu.
Zitieren
APA
Mager, L., Plaza, J. A., Sopkovich, J., Kaffenberger, B. H., & Dulmage, B. (2025). Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03694-7
Vancouver
Mager L, Plaza JA, Sopkovich J, Kaffenberger BH, Dulmage B. Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review. Archives of Dermatological Research. 2025. doi:10.1007/s00403-024-03694-7
BibTeX
@article{Mager2025,
author = {Mager, Layna and Plaza, Jose A and Sopkovich, Jennifer and Kaffenberger, Benjamin H and Dulmage, Brittany},
title = {Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review},
journal = {Archives of Dermatological Research},
year = {2025},
doi = {10.1007/s00403-024-03694-7}
}
EUVIMED